Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06726811 · ClinicalTrials.gov registry record

Droperidol and QTc Interval Changes in ED Patients

A clinical trial of Emergency Department Patient and QTc Intervals Changes, sponsored by CHRISTUS Health.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT06726811: Recruiting study of Emergency Department Patient and QTc Intervals Changes, sponsored by CHRISTUS Health.

NCT06726811 is a study of Emergency Department Patient and QTc Intervals Changes that is actively recruiting participants, run by CHRISTUS Health. The registered enrollment target is 500 participants, above the 247-participant average among 5 other Emergency Department Patient trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06726811, a study of Emergency Department Patient and QTc Intervals Changes, is actively recruiting participants, sponsored by CHRISTUS Health.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval. Hypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of IV Droperidol during an emergency department visit.

Primary Outcome

We plan to conduct ECG evaluation for QT interval both before and after patients are given 2.5 mg of droperidol.

Interventions

  • DRUG Droperidol injection

Study Locations (1)

Texas

  • CHRISTUS Spohn Hospital Corpus Christi-Shoreline - Corpus Christi

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-10-17
Est. Completion 2026-09-30
CHRISTUS Health

12 total trials

What NCT06726811 shows while recruiting

NCT06726811 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 247-participant average among 5 other Emergency Department Patient trials with a reported enrollment target (102% higher).

The record links to 2 conditions, with Emergency Department Patient appearing as the primary indexed condition, and to 1 intervention - of which Droperidol injection is the first listed.

NCT06726811 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06726811 about?

NCT06726811 is a clinical study titled "Droperidol and QTc Interval Changes in ED Patients". Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval. Hypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of ...

What is the current status of trial NCT06726811?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-10-17. Estimated completion is 2026-09-30.

What conditions does trial NCT06726811 study?

This clinical trial studies the following conditions: Emergency Department Patient, QTc Intervals Changes.

What interventions are being tested in trial NCT06726811?

The interventions under investigation include: Droperidol injection (DRUG).

Who is sponsoring clinical trial NCT06726811?

This trial is sponsored by CHRISTUS Health, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06726811 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Emergency Department Patient

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06726811, the US trial registry maintained by the National Library of Medicine. NCT06726811 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.